Lupus & antiphospholipid syndrome

Short- and mid-term outcomes in systemic lupus erythematosus patients presenting with disease exacerbation after SARS-CoV-2 mRNA vaccination: A cohort study from Puerto Rico

LupusPublished Cohort study

Authors' conclusion

In our group of SLE patients, 5.7% had a disease flare after SARS-CoV-2 mRNA vaccination. Most had exacerbations involving major organs/systems. Mucocutaneous manifestations, anti-Ro antibodies, disease activity, and corticosteroids were associated with flares.

Study context

Population
Puerto Ricans with systemic lupus erythematosus (SLE) who received mRNA COVID-19 vaccines
Participants
247 participants
Exposure
SLE patients with vs without exacerbation after SARS-CoV-2 mRNA vaccination
  • Post-vaccination exacerbationn = 14
Outcome
Post-vaccination SLE exacerbation (impact of SARS-CoV-2 mRNA vaccination on clinical course of SLE)

Main finding

As reported in the abstract

Post-vaccination exacerbation

Post-vaccination exacerbation

5.7%

14

Observational data: associations, not effects.

Further findings

OutcomeValues
Major organ involvement among patients with post-vaccination flaresPost-vaccination flares 71.4%

Baseline factors associated with post-vaccination flares

Photosensitivity, oral ulcers, anti-Ro antibodies, higher Systemic Lupus Erythematosus Disease Activity Index (SLEDAI) score, and corticosteroids exposure were associated with post-vaccination flares

Mean SLEDAI, ED visits, hospitalisations, disease damage and immunosuppressive drug exposure, before vs after vaccination

No significant differences before and after SARS-CoV-2 mRNA vaccination

Disease control among patients with flares · 12 months

All patients fully controlled without evidence of active disease

Original publication

Short- and mid-term outcomes in systemic lupus erythematosus patients presenting with disease exacerbation after SARS-CoV-2 mRNA vaccination: A cohort study from Puerto Rico. Lupus. Published 13 January 2023. doi:10.1177/09612033231151898

Composed by AI from the published abstract and checked against it. How Briefs are made →

Get them every week

New studies on this topic in My Week and in your Monday e-mail.

We e-mail you a sign-in link and a code. No password, no spam.